• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

修订后的预防措施以减少克雅氏病（CJD）通过血液及血液制品的可能传播；指导文件；可获取性——美国食品药品监督管理局。通知。

Revised precautionary measures to reduce the possible transmission of Creutzfeldt-Jakob disease (CJD) by blood and blood products; guidance document; availability--FDA. Notice.

出版信息

Fed Regist. 1997 Sep 23;62(184):49694-5.

PMID:10173801
Abstract

The Food and Drug Administration (FDA) is announcing the availability of a guidance document entitled "Revised Precautionary Measures to Reduce the Possible Transmission of Creutzfeldt-Jakob Disease (CJD) by Blood and Blood Products," dated December 11, 1996. The guidance document is intended to provide recommendations to the blood industry and may include information useful to other interested persons.

摘要

美国食品药品监督管理局（FDA）宣布可获取一份题为《修订后的预防措施，以减少克雅氏病（CJD）通过血液及血液制品的可能传播》的指导文件，日期为1996年12月11日。该指导文件旨在向血液行业提供建议，可能还包括对其他相关人士有用的信息。

相似文献

1
Revised precautionary measures to reduce the possible transmission of Creutzfeldt-Jakob disease (CJD) by blood and blood products; guidance document; availability--FDA. Notice.修订后的预防措施以减少克雅氏病（CJD）通过血液及血液制品的可能传播；指导文件；可获取性——美国食品药品监督管理局。通知。
Fed Regist. 1997 Sep 23;62(184):49694-5.
2
Interim recommendations for deferral of donors at increased risk for HIV-1 Group O infection; guidance document; availability--FDA. Notice.
Fed Regist. 1997 Sep 23;62(184):49695.
3
Guidance for industry: donor screening for antibodies to HTLV-II; availability--FDA. Notice.行业指南：人嗜T淋巴细胞病毒II型抗体供体筛查；可获取性——美国食品药品监督管理局。通知。
Fed Regist. 1998 Sep 29;63(188):51942-3.
4
"Guidance for industry: content and format of chemistry, manufacturing and controls information and establishment description information for a biological in vitro diagnostic product;" availability. Food and Drug Administration, HHS. Notice.工业指南：生物体外诊断产品的化学、制造和控制信息以及机构描述信息的内容和格式；可用性。美国卫生与公众服务部食品药品监督管理局。通知。
Fed Regist. 1999 Mar 8;64(44):11023-4.
5
"Guidance for Industry: For the Submission of Chemistry, Manufacturing and Controls and Establishment Description Information for Human Blood and Blood Components Intended for Transfusion or for Further Manufacture and for the Completion of the Form FDA 356h, 'Application to Market a New Drug, Biologic or an Antibiotic Drug for Human Use;'" availability. Food and Drug Administration, HHS. Notice.行业指南：用于输血或进一步制造的人血及血液成分的化学、制造与控制以及机构描述信息的提交，以及FDA 356h表格“人用新药、生物制品或抗生素药物上市申请”的填写；发布情况。美国卫生与公众服务部食品药品监督管理局。通知。
Fed Regist. 1999 May 10;64(89):25049-50.
6
"Guidance for Industry: On the Content and Format of Chemistry, Manufacturing and Controls Information and Establishment Description Information for an Allergenic Extract or Allergen Patch Test"; availability. Food and Drug Administration, HHS. Notice.
Fed Regist. 1999 Apr 23;64(78):20006-7.
7
"Guidance for industry: current good manufacturing practice for blood and blood components: (1). Quarantine and disposition of units from prior collections from donors with repeatedly reactive screening test for antibody to hepatitis C virus (anti-HCV); (2). Supplemental testing, and the notification of consignees and blood recipients of donor test results for anti-HCV;" availability--FDA. Notice.
Fed Regist. 1998 Oct 21;63(203):56198-9.
8
Variant Creutzfeldt-Jakob disease and prions in the blood supply.变异型克雅氏病与血液供应中的朊病毒
Clin Adv Hematol Oncol. 2004 Feb;2(2):84, 87, 131.
9
Creutzfeldt-Jakob disease: current U.S. policy to further reduce the possible risk of transmission by transfusion.克雅氏病：美国当前进一步降低输血传播潜在风险的政策。
Biologicals. 1996 Sep;24(3):277-83. doi: 10.1006/biol.1996.0035.
10
FDA wants more restrictions on donated blood.美国食品药品监督管理局希望对捐赠血液实施更多限制。
JAMA. 2001 Jul 25;286(4):408.